NRx Pharmaceuticals’ HOPE Therapeutics Deploys Zeta Surgical’s TMS Navigation System
NRx Pharmaceuticals’ subsidiary, HOPE Therapeutics, has become the first commercial site to deploy Zeta Surgical’s FDA-cleared TMS Navigation System at its West Palm Beach clinic. This system will aid in delivering precise image-guided Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other conditions. The technology utilizes AI to enhance targeting accuracy, aiming to improve treatment efficacy. The deployment supports HOPE’s comprehensive treatment model, which includes various therapies for depression and related disorders.
WEST PALM BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, “NRx” or the “Company”), a clinical-stage biopharmaceutical company, today announced that its wholly-owned subsidiary, HOPE Therapeutics, Inc. (“HOPE”), has become the first commercial site to deploy Zeta Surgical’s FDA-cleared Zeta TMS Navigation System. The system has been installed at HOPE’s West Palm Beach, Florida clinic, where it will be used to deliver high-precision, image-guided Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions.
